Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - salmonella typhimurium; thiomersal; aluminium hydroxide gel - parenteral liquid/solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 p; thiomersal mercury other 0.13 mg/ml; aluminium hydroxide gel mineral-aluminium-base other 0.0 p - immunotherapy - horse foal | horse mare (female) | female horse - salmonella typhimurium | vaccine | equine rotavirus

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

bioproperties pty. ltd. - salmonella typhimurium - oral solution/suspension - salmonella typhimurium vaccine-microbial active 0.0 undefined - immunotherapy - poultry chicks | turkey poult (young) | chickens | day old chicks | hatchlings | turkeys - day old poults | young turkey - salmonella enteridis | salmonella typhimurium | vaccine | equine rotavirus

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - salmonella typhi vi polysaccharide 25ug - solution for injection - 25µg/0.5ml - active: salmonella typhi vi polysaccharide 25ug excipient: dibasic sodium phosphate hydrochloric acid monobasic sodium phosphate dihydrate phenol sodium chloride sodium hydroxide water for injection - typhim vi™ is indicated for active immunisation against typhoid fever caused by salmonella typhi in individuals 2 years of age and over.

United States - English - NLM (National Library of Medicine)

sanofi pasteur inc. - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

United States - English - NLM (National Library of Medicine)

a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

United States - English - NLM (National Library of Medicine)

a-s medication solutions - salmonella typhi ty2 vi polysaccharide antigen (unii: 7194h8w3kt) (salmonella typhi ty2 vi polysaccharide antigen - unii:7194h8w3kt) - salmonella typhi ty2 vi polysaccharide antigen 25 ug in 0.5 ml - typhim vi vaccine is indicated for active immunization for the prevention of typhoid fever caused by s typhi and is approved for use in persons two years of age or older. immunization with typhim vi vaccine should occur at least two weeks prior to expected exposure to s typhi . typhim vi vaccine is not indicated for routine immunization of individuals in the united states (us). (14) selective immunization against typhoid fever is recommended under the following circumstances: 1) travelers to areas where a recognized risk of exposure to typhoid exists, particularly ones who will have prolonged exposure to potentially contaminated food and water, 2) persons with intimate exposure (ie, continued household contact) to a documented typhoid carrier, and 3) workers in microbiology laboratories who frequently work with s typhi . (14) typhoid vaccination is not required for international travel, but is recommended for travelers to such areas as africa, asia, and central and south america where there is a recognized r

United States - English - NLM (National Library of Medicine)

emergent travel health inc. - salmonella typhi ty21a live antigen (unii: 0mzi008m96) (salmonella typhi ty21a live antigen - unii:0mzi008m96) - salmonella typhi ty21a live antigen 6000000000 [cfu] - vivotif (typhoid vaccine live oral ty21a) is indicated for immunization of adults and children greater than 6 years of age against disease caused by salmonella typhi . routine typhoid vaccination is not recommended in the united states of america. selective immunization against typhoid fever is recommended for the following groups: 1) travelers to areas in which there is a recognized risk of exposure to s. typhi , 2) persons with intimate exposure (e.g. household contact) to a s. typhi carrier, and 3) microbiology laboratorians who work frequently with s. typhi (7). there is no evidence to support the use of typhoid vaccine to control common source outbreaks, disease following natural disasters or in persons attending rural summer camps. not all recipients of vivotif will be fully protected against typhoid fever. vaccinated individuals should continue to take personal precautions against exposure to typhoid organisms. the vaccine will not afford protection against species of salmonella other than salm

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zoetis australia pty ltd - salmonella typhimurium, awc 591 (live) - unknown - salmonella typhimurium, awc 591 (live) vaccine-microbial active 0.0 - active constituent

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - salmonella typhi vi polysaccharide, quantity: 0.025 mg - injection, solution - excipient ingredients: monobasic sodium phosphate; phenol; water for injections; sodium chloride; dibasic sodium phosphate dihydrate - for the active immunisation against typhoid fever, in subjects over 5 years of age. indications as at 9 october 2000: typhim vi is indicated for active immunisation against typhoid fever in subjects 2 years of age and over.

Malta - English - Medicines Authority

sanofi pasteur 14 espace henry vallée , 69007 lyon, france - vi polysaccharide, of salmonella, typhi - solution for injection - vi polysaccharide of salmonella typhi 25 µg - vaccines